Skip to content

Predict Arrhythmia Risk Using Intelligent Software

Artificial Intelligence-based Prediction and Detection of Critical Arrhythmias in Acute Cardiac Illness.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07792694
Acronym
PARIS
Enrollment
3000
Registered
2026-08-28
Start date
2023-01-01
Completion date
2029-04-01
Last updated
2026-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction (AMI), Cardiac Arrhythmias, Ventricular Fibrillation, Ventricular Tachycardia (VT)

Keywords

Ventricular Tachycardia, Ventricular Fibrillation, Acute myocardial infarction, Electrocardiography, Machine Learning, Artificial Intelligence, Deep Learning, Convolutional Neural Network, CNN, Prediction model

Brief summary

Cardiac arrhythmias frequently occur in patients admitted to the Coronary Care Unit (CCU). The majority of these patients are treated for an acute myocardial infarction, which carries an increased risk of life-threatening arrhythmias such as ventricular tachycardia (VT) or ventricular fibrillation (VF). This risk is one of the reasons these patients are monitored for 48 hours after a myocardial infarction, in accordance with the guidelines of the European Society of Cardiology (ESC) for acute coronary syndrome. Other arrhythmias, such as asystole, atrial fibrillation, or atrioventricular block, also occur in CCU patients. These arrhythmias are recorded on the electrocardiogram (ECG) monitor in the CCU and trigger an alarm for healthcare staff. However, in order to apply this alarming with sufficient sensitivity, many false positive alarms are also produced, which increases the workload for nurses (alarm fatigue) and undermines patient well-being. This study will investigate whether Artificial Intelligence (AI) models, using continuous ECG data, can help improve the prediction of patients at risk of a life-threatening cardiac arrhythmia. Firstly, this study will aim to predict patients at risk of VT/VF in both the short term (30 minutes) and long term (1 day) in patients under continuous telemetric monitoring. This prediction facilitates timely intervention by the team in the short term, and in the long term, the safe transfer of a patient to a lower-complexity ward or earlier safe discharge of a patient. Secondly, this study will aim for improved detection to reduce the number of false negative alarms and thereby reduce alarm fatigue. The performance of these AI models can be evaluated through this retrospective observational study. Patients aged 18 years or older who have been admitted with acute cardiac disease will be included. The primary objective of this study will be to evaluate the performance of AI models that detect and predict critical arrhythmias in the short and long term, using ECG data obtained via the monitoring system.

Detailed description

Primary objective: Assessment of the performances of AI models in identifying patients at risk of sustained VT and VF from bedside monitor ECG in different timeframes: * 30-minute prediction model * 1-day prediction model Secondary objectives: • Assessment of potential healthcare savings if the AI model in would be used in clinical practice, such as CCU length-of-stay (CCU-LOS), hospital length-of-stay and associated costs Exploratory objectives: * Real time and continuous detection of events for alarming * Prediction of other types of arrhythmias (e.g., Atrial fibrillation (AF), atrioventricular block, severe brady-arrhythmia) using in hospital ECG monitoring. * Identification of clinical risk factors for sustained VT and/or VF * Exploration of development and assessment of new AI models using new (clinical) input

Interventions

None listed

Sponsors

Catharina Ziekenhuis Eindhoven
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients admitted from 1/1/2023\* * Patients aged 18 years or older * Admitted for acute cardiac illness or after elective cardiac procedures * Who are on ECG monitoring in the CCU, ICU or ward * Patients for whom continuous waveform ECG data have been routinely stored. * Continuous waveform ECG data has been routinely stored in the CZE since 1/1/2023 on the ICU, since 1/12/2025 on the CCU and on the ward it has yet to be implemented. As our project utilizes this continuous ECG data, it will only include patients for whom this data is available.

Exclusion criteria

\- Patients who expressed their preference for not having their data used for scientific research or to improve quality of care in the opt-out program of the CZE.

Design outcomes

Primary

MeasureTime frameDescription
Occurrence of sustained ventricular tachycardia or ventricular fibrillationDuring admissionThe primary outcome of the study is the occurrence of sustained ventricular tachycardia (VT) (monomorphic and polymorphic with a heartrate \> 100 bpm and duration \> 30 seconds or with hemodynamic compromise such as fainting or need for resuscitation) or ventricular fibrillation. (Binary outcome measure 0 = no event during admission, 1 = event during admission)

Secondary

MeasureTime frameDescription
Secondary outcome measureDuring admission\- A 'textbook' outcome (no adverse events) (Binary outcome measure 0 = no event during admission, 1 = event during admission)
Secondary Outcome Measureduring admission\- In-hospital onset and offset of cardiac arrhythmias (e.g. atrial fibrillation, atrio-ventricular block or severe tachy- or bradyarrhythmia, non-sustained VT). (Binary outcome measure 0 = no event during admission, 1 = event during admission)
Performance of AI prediction modelDuring admissionDiscrimination of AI prediction model expressed with Area Under the Receiver Operating Characteristic curve (AUROC), Area Under the Precision-Recall Curve (AUPRC), sensitivity, specificity, (Positive Predictive Value) PPV and (Negative Predictive Value) NPV

Countries

Netherlands

Contacts

CONTACTMaud E Kortman, M.D.
maud.kortman@catharinaziekenhuis.nl040 239 9111
CONTACTLuuk C Otterspoor, Dr. M.D.
luuk.otterspoor@catharinaziekenhuis.nl
PRINCIPAL_INVESTIGATORLuuk C Otterspoor, Dr. M.D.

Catharina Ziekenhuis Eindhoven

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 29, 2026